Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias

[1]  C. Eaves,et al.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Willingham,et al.  High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. , 1999, Protein expression and purification.

[3]  M. Willingham,et al.  Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. , 1999, Leukemia research.

[4]  J. McCubrey,et al.  Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells , 1998, Leukemia.

[5]  C. Eaves,et al.  Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. , 1998, Blood.

[6]  Y. Kagami,et al.  Analysis of bax protein in sphingosine-induced apoptosis in the human leukemic cell line TF1 and its bcl-2 transfectants. , 1998, Experimental hematology.

[7]  M. Urashima,et al.  MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. , 1998, Blood.

[8]  C. Eaves,et al.  Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. , 1998, Blood.

[9]  A. Frankel,et al.  Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. , 1998, Bioconjugate chemistry.

[10]  F. Cavalli,et al.  Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites , 1998, Cancer Chemotherapy and Pharmacology.

[11]  T. Tabira,et al.  Interleukin‐3 and Interleukin‐3 Receptors in the Brain a , 1998, Annals of the New York Academy of Sciences.

[12]  R. Kreitman.  IBC's international Conference on Novel Therapeutic Proteins for Oncology (drug discovery and development). , 1998, Expert opinion on investigational drugs.

[13]  S. Olsnes,et al.  Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N‐end rule pathway , 1998, The EMBO journal.

[14]  M. Willingham,et al.  Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. , 1997, Blood.

[15]  L. Ailles,et al.  Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. , 1997, Blood.

[16]  I. Pastan,et al.  Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. , 1997, Blood.

[17]  D. Gillet,et al.  Characterization and receptor specific toxicity of two diphtheria toxin‐related interleukin‐3 fusion proteins DAB389–mIL‐3 and DAB389–(Gly4Ser)2‐mIL‐3 , 1997, FEBS letters.

[18]  S. Korsmeyer,et al.  bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  F. Cavalli,et al.  Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. , 1997, British Journal of Cancer.

[20]  A. Miyajima,et al.  Expression of IL-3 receptor in testis. , 1996, Biochemical and biophysical research communications.

[21]  B. Blazar,et al.  Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells. , 1996, Blood.

[22]  A. List,et al.  Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.

[23]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.

[24]  J. McCubrey,et al.  Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells. , 1996, Leukemia.

[25]  J. Gamble,et al.  IL‐3 receptor expression, regulation and function in cells of the Vasculature. , 1996, Immunology and cell biology.

[26]  R. Fanin,et al.  Evaluation of the clinical relevance of the anionic glutathione-s-transferase (GST pi) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas. , 1994, Leukemia & lymphoma.

[27]  R. Pirker,et al.  MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. , 1993, Leukemia & lymphoma.

[28]  S. Ikehara,et al.  Separation of hematopoietic stem cells into two populations and their characterization. , 1992, Blood.

[29]  A. Miyajima,et al.  Two distinct functional high affinity receptors for mouse interleukin‐3 (IL‐3). , 1992, The EMBO journal.

[30]  C. Langefeld,et al.  Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. , 1991, Experimental hematology.

[31]  T. Waldmann,et al.  The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Cannistra,et al.  Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. , 1990, The Journal of biological chemistry.

[33]  E. Estey,et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Miyazono,et al.  Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin , 1989, Journal of cellular physiology.

[35]  I. Bernstein,et al.  Interleukin-3, GM-CSF, and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. , 1989, Blood.

[36]  P. Casellas,et al.  An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensin , 1989, International journal of cancer.

[37]  M. Minden,et al.  The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture. , 1988, Leukemia.

[38]  R. Youle,et al.  Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. , 1987, Science.

[39]  H. Kantarjian,et al.  Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.

[40]  P. Nowell,et al.  Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines , 1987 .

[41]  I. Pastan,et al.  Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.

[42]  J. Ihle,et al.  Permissive role of interleukin 3 (IL‐3) in proliferation and differentiation of multipotential hemopoietic progenitors in culture , 1985, Journal of cellular physiology.

[43]  S. Goodman,et al.  A structural model of human erythrocyte band 2.1: alignment of chemical and functional domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Liber,et al.  Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. , 1982, Mutation research.

[45]  Peter Ralph,et al.  Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia , 1976, International journal of cancer.

[46]  P. Ralph,et al.  Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line , 1975, Nature.

[47]  R. Collier,et al.  Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. , 1971, The Journal of biological chemistry.

[48]  R. Collier,et al.  Structure and activity of diphtheria toxin. I. Thiol-dependent dissociation of a fraction of toxin into enzymically active and inactive fragments. , 1971, The Journal of biological chemistry.

[49]  S Farber,et al.  Morphologic variations in human leukemic lymphoblasts (CCRF‐CEM cells) after long‐term culture and exposure to chemotherapeutic agents: A study with the electron microscope , 1966, Cancer.

[50]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[51]  P. Ponath.  Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS. , 1998, Expert opinion on investigational drugs.

[52]  Larry J. Smith,et al.  Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. , 1990, Blood.

[53]  P. Matsudaira.  A Practical guide to protein and peptide purification for microsequencing , 1989 .

[54]  D. Hilton,et al.  Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSF, G-CSF) receptors by normal hemopoietic cells and cell lines. , 1988, Growth factors.

[55]  E. Freireich,et al.  HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. , 1988, Blood.